Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model
Autore:
du Toit, E; Hofmann, D; McCarthy, J; Pineda, C;
Indirizzi:
Univ Cape Town, MRC Interuniv Cape Heart Res Grp, ZA-7925 Cape Town, SouthAfrica Univ Cape Town Cape Town South Africa ZA-7925 925 Cape Town, SouthAfrica Natl Accelerator Ctr, Cape Town, South Africa Natl Accelerator Ctr Cape Town South Africa tr, Cape Town, South Africa
Titolo Testata:
HEART
fascicolo: 1, volume: 86, anno: 2001,
pagine: 81 - 87
SICI:
1355-6037(200107)86:1<81:EOLOMC>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
MEDIATED CALCIUM SENSITIZATION; CONVERTING-ENZYME-INHIBITOR; CHRONIC ORAL PRETREATMENT; SENSITIVE K+ CHANNEL; VENTRICULAR-FIBRILLATION; STUNNED MYOCARDIUM; TROPONIN-C; SARCOPLASMIC-RETICULUM; ISOMETRIC TENSION; HEART;
Keywords:
calcium sensitisers; myocardial ischaemia; arrhythmias;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: du Toit, E Univ Stellenbosch, Fac Hlth Sci, Dept Med Physiol, POB 19036, ZA-7505 Tygerberg, South Africa Univ Stellenbosch POB 19036 Tygerberg SouthAfrica ZA-7505 ica
Citazione:
E. du Toit et al., "Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model", HEART, 86(1), 2001, pp. 81-87

Abstract

Objective-To determine whether levosimendan, a calcium sensitiser that facilitates the activation of the contractile apparatus by calcium, improves myocardial contractile function during severe ischaemia and reperfusion without exacerbating the incidence of arrhythmias. Design-Pigs were pretreated orally twice daily for 10 days with 0.08 mg/kglevosimendan or placebo. On day 11 the left main coronary artery was ligated for 30 minutes, followed by 30 minutes of reperfusion. A bolus dose of levosimendan, 11.2 mug/kg intravenously, or placebo was given 30 minutes before coronary ligation, followed by a continuous infusion of 0.2 mug/kg/min levosimendan or placebo for the remainder of the experiment. Results-During the ischaemic period, cardiac output was higher in the levosimendan group than in the placebo group (mean (SD): 2.6 (0.5) v 2.0 (0.2) l/min, p < 0.05) and systemic vascular resistance was lower (2024 (188) v 2669 (424) dyne.s(-1).cm(-5), p < 0.005). During reperfusion, cardiac outputand contractility (LV(max)dP/dt (pos), 956 (118) v 784 (130) mm Hg/s, p < 0.05) were increased by levosimendan. The incidence of ischaemic ventricular fibrillation and tachycardia was similar in the two groups but there weremore arrhythmic events (ventricular tachycardia and ventricular fibrillation) in the levosimendan treated group (8/12 levosimendan v 1/9 control p = 0.05). Conclusions-Levosimendan improved cardiac output and myocardial contractility during coronary artery ligation and reperfusion. However, it increased the number of arrhythmic events during ischaemia in this model of in vivo regional ischaemia.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/02/20 alle ore 20:52:42